A multicenter, randomized, double-blind, 8 week study to evaluate the dose response, efficacy and safety of aliskiren in pediatric hypertensive patients 6-17 years of age

Principal Investigator - Karen McNiece Redwine, M.D.

The study will evaluate various doses for aliskiren and placebo in children to see which is better tolerated and most effective. Children between the ages of 6-17 years with high blood pressure are currently being enrolled.
Requires multiple office visits over a two month period, includes at no cost to you or your child:
• Lab Testing
• Physical Exam
• Study Medication
• Blood Pressure Monitor for Home Use

Compensation is provided for time and travel.
Contact Lee Howard at 501-364-6990 or at pager number 501-395-6700.